13-deoxytedanolide: structure in first source
ID Source | ID |
---|---|
PubMed CID | 16040283 |
MeSH ID | M0363959 |
Synonym |
---|
13-deoxytedanolide |
(3r,4s,5s,7r,8r,9e,11s,15r,17r)-3,8-dihydroxy-17-[(s)-hydroxy{(2r,3r)-2-methyl-3-[(1s,2z)-1-methylbut-2-en-1-yl]oxiran-2-yl}methyl]-4-methoxy-5,7,9,11,15-pentamethyloxacyclooctadec-9-ene-2,6,12,16-tetrone (non-preferred name) |
Q27451661 |
(3r,4s,5s,7r,8r,9e,11s,15r,17r)-3,8-dihydroxy-17-[(s)-hydroxy-[(2r,3r)-2-methyl-3-[(z,2s)-pent-3-en-2-yl]oxiran-2-yl]methyl]-4-methoxy-5,7,9,11,15-pentamethyl-1-oxacyclooctadec-9-ene-2,6,12,16-tetrone |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (7.69) | 18.2507 |
2000's | 10 (76.92) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.69%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (92.31%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |